Method for extracting plumbagin

By employing methods such as alcohol extraction, molecularly imprinted microsphere purification, albumin-PEG complex encapsulation, and folic acid modification, the problem of poor water solubility of pistachiosin was solved, improving the extraction rate and efficacy, enhancing the sensitivity to chemotherapy-resistant and radiation-resistant cancer cells, and improving the anti-tumor effect in synergistic effect with chemotherapy drugs.

CN119039126APending Publication Date: 2024-11-29YONGZHOU VOCATIONAL & TECH COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411268283.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The poor water solubility of peony root extract leads to low extraction efficiency, which limits its application in the field of anti-tumor therapy. It also has problems such as poor cell specificity, poor pharmacokinetics, and high toxicity.

Method used

A folic acid-modified plumbagoside-encapsulated complex was prepared by using alcohol extraction, molecularly imprinted microsphere purification, albumin-PEG complex encapsulation, and folic acid modification. This complex enhances drug uptake and efficacy in tumor cells through active transport.

Benefits of technology

It significantly improved the extraction rate and water solubility of peony root extract, enhanced its sensitivity to chemotherapy-resistant and radiation-resistant cancer cells, and enhanced the anti-tumor effect in synergistic effect with chemotherapy drugs, while reducing the side effects of chemotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides an extraction method of plumbagin, and belongs to the technical field of medicines. Comprising the following steps: S1, washing, drying and crushing plumbago zeylanica to obtain plumbago zeylanica powder, adding the plumbago zeylanica powder into an ethanol solution, and performing heating reflux extraction, filtration and concentration to obtain a plumbago zeylanica alcohol extract; s2, purifying the plumbago zeylanica alcohol extract by using molecularly imprinted microspheres to obtain plumbagin; s3, albumin is dissolved in water, NHS and EDC.HCl are added, stirring activation is performed, NH2-PEG-COOH is added, stirring reaction and ultrafiltration are performed, and an albumin-PEG compound is prepared; s4, adding the albumin-PEG compound, EDC.HCl and DMAP into water, adding plumbagin, carrying out stirring reaction, and carrying out ultrafiltration, so as to obtain an embedded compound; s5, performing folic acid modification to obtain the folic acid modified plumbagin embedding compound. The method is green, environment-friendly, low in cost, high in extraction rate, good in separation selectivity and wide in application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to a method for extracting plumbagin. Background Art

[0002] Plumbago zeylanica, belonging to the family Plumbago, is also known as white snowflake and Yijianxiao. It is a subshrubby herb with a bitter taste and a slightly warm nature. It is mainly distributed in Southeast Asia and South China and Southwest my country. Plumbago contains a variety of chemical components such as naphthoquinones, coumarins, organic acids, and sterols, and has a wide range of pharmacological activities. The plumbago in its components is an important material basis for the antibacterial, anti-inflammatory, and anti-cancer biological activities of Plumbago.

[0003] Plumbagin, also known as blue snow quinone, is a highly lipid-soluble naphthoquinone compound with a chemical name of 5-hydroxy-2-methyl-l,4-naphthoquinone. Plumbagin extract has multiple pharmacological effects, including reducing the proliferation of liver fibers in experimental liver fibrosis mice, antibacterial, anti-allergic, anti-leukemia, anti-cancer (liver cancer), and anti-hyperglycemia. Although plumbagin has good pharmacological activity, its poor water solubility greatly limits its extraction efficiency. Therefore, how to improve the extraction rate of plumbagin will be of significant significance. Summary of the invention

[0004] The purpose of the present invention is to provide a method for extracting plumbagin, which is not only simple in preparation method, green and environmentally friendly, low in cost, high in extraction rate, good in separation selectivity, but also has high solubility of the obtained product, can re-sensitize chemotherapy-resistant and radiation-resistant cancer cells, greatly improve the drug efficacy, and has broad application prospects.

[0005] The technical solution of the present invention is achieved in this way: The present invention provides a method for extracting plumbagin, comprising the following steps: S1. Alcohol extraction: Wash, dry and crush the plumbaginous plant to obtain plumbaginous plant powder, add it to an ethanol solution, heat and reflux it for extraction, repeat the extraction, filter, combine the filtrate and concentrate it to obtain an alcohol extract of plumbaginous plant; S2. Purification: The molecularly imprinted microspheres were loaded into a column, and the plumbagin alcohol extract was added, and the ethanol solution mixture was eluted, the eluate was collected, and the solvent was removed under reduced pressure to obtain plumbagin; S3. Preparation of albumin-PEG complex: dissolve albumin in water, add NHS and EDC·HCl, stir to activate, add NH2-PEG-COOH, stir to react, remove unreacted raw materials by ultrafiltration, and prepare albumin-PEG complex; S4. Encapsulation: adding albumin-PEG complex, EDC·HCl and DMAP to water, adding plumbagin, stirring to react, and removing unreacted raw materials by ultrafiltration to obtain an encapsulation complex; S5. Folic acid modification: Dissolve folic acid in dimethyl sulfoxide and triethanolamine, add NHS and DCC, stir the reaction in the dark, evaporate under pressure, add the product and the embedding complex into water, adjust the pH value, stir in the dark, incubate, and obtain the folic acid-modified plumbagin embedding complex.

[0006] As a further improvement of the present invention, the concentration of the ethanol solution in step S1 is 60-70wt%, the heating reflux extraction time is 3-5h, the extraction is repeated 2-3 times, and the concentration is to 1 / 2 to 1 / 3 of the original volume.

[0007] As a further improvement of the present invention, the concentration of the ethanol solution in step S2 is 65-75wt%, and the preparation method of the molecularly imprinted microspheres is as follows: T1. Plumbingol, functional monomers, crosslinking agents, and porogens were mixed and added to water. Under inert gas protection, an initiator was added, the polymerization reaction was heated, filtered, dried, and ball-milled to obtain polymer microspheres. T2. Add the polymer microspheres prepared in step T1 into a Soxhlet extractor, use an eluent to remove plumbagin, wash, and dry to obtain molecularly imprinted microspheres.

[0008] As a further improvement of the present invention, the mass ratio of plumbagin, functional monomer, cross-linking agent, porogen and initiator is 6-7:29-32:0.2-0.7:1-2:0.05-0.15, the initiator is selected from at least one of sodium persulfate, potassium persulfate and ammonium persulfate, the functional monomer includes 4-vinylpyridine and butyl methacrylate in a mass ratio of 12-15:4-7, the cross-linking agent is ethylene glycol dimethacrylate, the porogen is acetone, the temperature of the heating polymerization reaction is 55-65°C, and the time is 1-3h.

[0009] As a further improvement of the present invention, the mass ratio of albumin, NHS, EDC·HCl and NH2-PEG-COOH in step S3 is 10:3-5:5-7:12-15, the stirring activation temperature is 0-4°C, the time is 20-40min, and the stirring reaction time is 3-4h.

[0010] As a further improvement of the present invention, in step S4, the mass ratio of the albumin-PEG complex, EDC·HCl, DMAP, and plumbagin is 12-15:2-4:0.5-1:5-7, and the stirring reaction time is 30-50 min.

[0011] As a further improvement of the present invention, the mass ratio of folic acid, dimethyl sulfoxide, triethanolamine, NHS and DCC in step S5 is 0.5:1.8-2.2:0.05-0.1:0.05-0.07:0.06-0.1, the mass ratio of the product and the embedding complex is 3-5:10, the time for the light-proof stirring reaction is 1-3h, the pH value is adjusted to 9.5-10.5, the time for the light-proof stirring is 1-3h, the incubation temperature is 3-5°C, and the time is 10-12h.

[0012] The present invention further protects a folic acid-modified plumbagin embedding complex prepared by the above extraction method.

[0013] The present invention further protects an anti-tumor composition, comprising the above-mentioned folic acid-modified plumbagin embedding complex and paclitaxel and cisplatin.

[0014] As a further improvement of the present invention, the mass ratio of the folic acid-modified plumbagin embedding complex to paclitaxel and cisplatin is 1-2:7-9:8-10.

[0015] The present invention has the following beneficial effects: Plumbagin has good anti-tumor effects, but its therapeutic potential is limited due to its lack of cell specificity, poor pharmacokinetics and low lipophilicity, which leads to low cellular uptake. In addition, plumbagin is highly toxic and has poor water solubility, which limits its research and application in anti-tumor.

[0016] The present invention has a good effect of promoting the dissolution of plumbagin in plumbagin through alcohol extraction, but at the same time, most of other impurities are also extracted, so the purity of the prepared plumbagin alcohol extract is not high.

[0017] The invention adopts the prepared molecular imprinting microspheres to purify the plumbagin alcohol extract, and the molecular imprinting polymer can highly selectively separate and obtain plumbagin, which is green and environmentally friendly, has high efficiency, low cost, small solvent consumption, good separation selectivity, and the used molecular imprinting microspheres can be regenerated and reused, thereby greatly reducing the cost of purification.

[0018] Human serum albumin is a transport protein that plays a vital role in drug metabolism. Nanoparticles made of human serum albumin can be used as drug transport carriers to improve the solubility of drugs and increase the therapeutic effect in the body. Through passive transport, drugs are delivered to cells to exert their efficacy. However, this effect of improving drug solubility is not obvious, and protein compounds are easily enzymatically hydrolyzed during transportation. Therefore, a better method is needed.

[0019] The present invention uses albumin modified with polyethylene glycol (PEG), which effectively protects the protein from being hydrolyzed by enzymes while improving solubility, and can deliver the protein-loaded drug into cells to achieve regulation of cell physiological functions. At the same time, albumin modified with polyethylene glycol can also increase the loading amount of the drug plumbagin, improve the water solubility of plumbagin, and also improve its efficacy.

[0020] In addition, the surface of the prepared embedded complex is modified with folic acid in the present invention. Through active transport, the surface of tumor cells will overexpress folic acid receptors, so that the folic acid-modified nanoparticles can bind to the receptors of tumor cells and enter the cells through endocytosis to enhance the therapeutic effect. Therefore, after folic acid modification, chemotherapy-resistant and radiation-resistant cancer cells can be re-sensitized, greatly improving the efficacy of the drug.

[0021] Plumbagin can play an anti-tumor role by inducing apoptosis and autophagy, inhibiting proliferation, invasion and metastasis, and anti-angiogenesis. Plumbagin can also play an anti-tumor role by inducing ferroptosis. At the same time, when used in combination with chemotherapy drugs, plumbagin can re-sensitize chemotherapy-resistant and radiation-resistant cancer cells and improve the anti-tumor effect.

[0022] Plumbagin can reduce the phosphorylation level of extracellular signal-regulated kinase (ERK) in breast cancer cells and eliminate paclitaxel-induced ERK phosphorylation. In addition, plumbagin can reduce the phosphorylated ERK level in paclitaxel-resistant breast cancer cells and resensitize paclitaxel-resistant cells to the compound. Plumbagin can also synergistically inhibit the viability, apoptosis and autophagy of tongue squamous cell carcinoma cells by increasing intracellular ROS. Its mechanism of action may be to resensitize cisplatin-resistant cells to the compound by activating c-Jun amino-terminal kinase (JNK) and inhibiting AKT / mTOR signaling pathway. The synergistic use of plumbagin, paclitaxel and cisplatin can greatly improve the anti-tumor efficiency, enhance the promotion of tumor cell apoptosis through multiple pathways, and have a certain protective effect on normal cells, thereby helping to reduce the side effects of chemotherapy, and can also increase the sensitivity of cells, improve the efficacy, reduce the amount of chemotherapy drugs used, and thus reduce side effects. DETAILED DESCRIPTION

[0023] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0024] O-(2-aminoethyl)-O'-(2-carboxyethyl) polyethylene glycol 5000 (NH2-PEG-COOH, MW = 5ku, Shanghai Yanyi Biotechnology Co., Ltd.); 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl, 98.5%, Aladdin Reagent Co., Ltd.); 4-dimethylaminopyridine (DMAP, 99%, Aladdin Reagent Co., Ltd.); N-hydroxysuccinimide (NHS, Aladdin Reagent Co., Ltd.).

[0025] Preparation Example 1 Preparation of molecularly imprinted microspheres Here’s how: T1. 6g of plumbagin, 29g of functional monomer, 0.2g of ethylene glycol dimethacrylate and 1g of acetone were mixed and added into water. Under nitrogen protection, 0.05g of potassium persulfate was added and heated to 55°C for 1h of polymerization. The mixture was filtered, dried and ball-milled to obtain polymer microspheres. The functional monomers include 4-vinylpyridine and butyl methacrylate in a mass ratio of 12:4; T2. Add the polymer microspheres prepared in step T1 into a Soxhlet extractor, use an eluent to remove plumbagin, wash, and dry to obtain molecularly imprinted microspheres.

[0026] Preparation Example 2 Preparation of molecularly imprinted microspheres Here’s how: T1. 7g of plumbagin, 32g of functional monomer, 0.7g of ethylene glycol dimethacrylate and 2g of acetone were mixed and added into water. Under nitrogen protection, 0.15g of ammonium persulfate was added and heated to 65°C. The polymerization reaction was carried out for 3h. The mixture was filtered, dried and ball-milled to obtain polymer microspheres. The functional monomers include 4-vinylpyridine and butyl methacrylate in a mass ratio of 15:7; T2. Add the polymer microspheres prepared in step T1 into a Soxhlet extractor, use an eluent to remove plumbagin, wash, and dry to obtain molecularly imprinted microspheres.

[0027] Preparation Example 3 Preparation of molecularly imprinted microspheres Here’s how: T1. 6.5g of plumbagin, 30g of functional monomer, 0.5g of ethylene glycol dimethacrylate and 1.5g of acetone were mixed and added into water. Under nitrogen protection, 0.1g of sodium persulfate was added and heated to 60°C for polymerization for 2h. The mixture was filtered, dried and ball-milled to obtain polymer microspheres. The functional monomers include 4-vinylpyridine and butyl methacrylate in a mass ratio of 13:5; T2. Add the polymer microspheres prepared in step T1 into a Soxhlet extractor, use an eluent to remove plumbagin, wash, and dry to obtain molecularly imprinted microspheres.

[0028] Example 1 The present embodiment provides a method for extracting plumbagin, comprising the following steps: S1. Alcohol extraction: The plumbago was washed, dried, and crushed to obtain plumbago powder, added to a 60wt% ethanol solution, heated under reflux for 3h, and the extraction was repeated twice, filtered, and the filtrates were combined and concentrated to 1 / 2 of the original volume to obtain a plumbago alcohol extract; S2. Purification: The imprinted microspheres prepared in Preparation Example 1 were loaded onto a column, and the alcohol extract of plumbagin was added, eluted with a 65wt% ethanol solution mixture, the eluate was collected, and the solvent was removed under reduced pressure to obtain plumbagin; S3. Preparation of albumin-PEG complex: 10 g albumin was dissolved in 500 mL water, 3 g NHS and 5 g EDC·HCl were added, and the mixture was activated by stirring at 0°C for 20 min, 12 g NH2-PEG-COOH was added, and the mixture was reacted by stirring for 3 h. The unreacted raw materials were removed by ultrafiltration to obtain the albumin-PEG complex. S4. Encapsulation: 12 g of albumin-PEG complex, 2 g of EDC·HCl and 0.5 g of DMAP were added to 500 mL of water, 5 g of plumbagin was added, and the mixture was stirred for 30 min. Unreacted raw materials were removed by ultrafiltration to obtain an encapsulation complex; S5. Folic acid modification: Dissolve 0.5 g of folic acid in 1.8 g of dimethyl sulfoxide and 50 mg of triethanolamine, add 50 mg of NHS and 60 mg of DCC, stir in the dark for 1 h, evaporate under pressure, add 0.3 g of the product and 1 g of the embedding complex into 200 mL of water, adjust the pH value to 9.5, stir in the dark for 1 h, incubate at 3°C ​​for 10 h, and obtain the folic acid-modified plumbagin embedding complex.

[0029] Example 2 The present embodiment provides a method for extracting plumbagin, comprising the following steps: S1. Alcohol extraction: The plumbago was washed, dried, and crushed to obtain plumbago powder, which was added to a 70wt% ethanol solution and heated under reflux for 5h. The extraction was repeated three times, filtered, and the filtrates were combined and concentrated to 1 / 3 of the original volume to obtain a plumbago alcohol extract; S2 purification: The imprinted microspheres prepared in Preparation Example 2 were loaded onto a column, and the alcohol extract of plumbagin was added, eluted with a 75wt% ethanol solution mixture, the eluate was collected, and the solvent was removed under reduced pressure to obtain plumbagin; S3. Preparation of albumin-PEG complex: 10 g albumin was dissolved in 500 mL water, 5 g NHS and 7 g EDC·HCl were added, and the mixture was stirred and activated at 4°C for 40 min. 15 g NH2-PEG-COOH was added, and the mixture was stirred and reacted for 4 h. The unreacted raw materials were removed by ultrafiltration to obtain the albumin-PEG complex. S4. Encapsulation: 15 g of albumin-PEG complex, 4 g of EDC·HCl and 1 g of DMAP were added to 500 mL of water, 7 g of plumbagin was added, and the mixture was stirred for 50 min. Unreacted raw materials were removed by ultrafiltration to obtain an encapsulation complex; S5. Folic acid modification: Dissolve 0.5 g of folic acid in 2.2 g of dimethyl sulfoxide and 100 mg of triethanolamine, add 70 mg of NHS and 100 mg of DCC, stir in the dark for 3 h, evaporate under pressure, add 0.5 g of the product and 1 g of the embedding complex into 200 mL of water, adjust the pH value to 10.5, stir in the dark for 3 h, incubate at 5°C for 12 h, and obtain the folic acid-modified plumbagin embedding complex.

[0030] Example 3 The present embodiment provides a method for extracting plumbagin, comprising the following steps: S1. Alcohol extraction: The plumbago was washed, dried, and crushed to obtain plumbago powder, added to a 65wt% ethanol solution, heated under reflux for 4h, and the extraction was repeated 3 times, filtered, and the filtrate was combined and concentrated to 1 / 3 of the original volume to obtain a plumbago alcohol extract; S2. Purification: The imprinted microspheres prepared in Preparation Example 3 were loaded onto a column, and the alcohol extract of plumbagin was added, eluted with a mixed solution of 70wt% ethanol solution, the eluate was collected, and the solvent was removed under reduced pressure to obtain plumbagin; S3. Preparation of albumin-PEG complex: 10 g albumin was dissolved in 500 mL water, 4 g NHS and 6 g EDC·HCl were added, and the mixture was activated by stirring at 2°C for 30 min, 13 g NH2-PEG-COOH was added, and the mixture was reacted by stirring for 3.5 h. Unreacted raw materials were removed by ultrafiltration to obtain albumin-PEG complex; S4. Encapsulation: 13 g of albumin-PEG complex, 3 g of EDC·HCl and 0.7 g of DMAP were added to 500 mL of water, 6 g of plumbagin was added, and the mixture was stirred for 40 min. Unreacted raw materials were removed by ultrafiltration to obtain an encapsulation complex; S5. Folic acid modification: Dissolve 0.5 g of folic acid in 2 g of dimethyl sulfoxide and 70 mg of triethanolamine, add 60 mg of NHS and 80 mg of DCC, stir in the dark for 2 h, evaporate under pressure, add 0.4 g of the product and 1 g of the embedding complex into 200 mL of water, adjust the pH value to 10, stir in the dark for 2 h, incubate at 4°C for 11 h to obtain the folic acid-modified plumbagin embedding complex.

[0031] Comparative Example 1 Compared with Example 3, the difference is that the concentration of the ethanol solution in step S1 is 80wt%.

[0032] Comparative Example 2 Compared with Example 3, the difference is that macroporous resin AB-8 is used for purification in step S2.

[0033] Comparative Example 3 Compared with Example 3, the difference is that step S3 is not performed, and albumin is used for embedding in step S4.

[0034] Comparative Example 4 Compared with Example 3, the difference is that step S3 is not performed, and NH2-PEG-COOH is used for embedding in step S4.

[0035] Comparative Example 5 Compared with Embodiment 3, the difference is that step S5 is not performed.

[0036] Test Example 1 Weigh 0.1 g of the folate-modified plumbagin embedding complex prepared in Example 1-3 and Comparative Example 1-4 and dissolve it in acetonitrile solution, and centrifuge it at 5000 r / min for 10 min. Measure the amount of plumbagin by HPLC (HPLC analysis method: chromatographic column, Yuexu Xtimate C18 column (5 mm×250 mm, 5 μm); mobile phase, V (methanol): V (sodium dihydrogen phosphate (5 mm)) = 9:1; flow rate 1 mL / min; column temperature 30°C; detection wavelength 265 nm). Calculate the drug loading (DL): Drug loading (%) = weight of plumbagin in folic acid-modified plumbagin embedding complex / weight of plumbagin × 100% The results are shown in Table 1.

[0037] Table 1

[0038] It can be seen from the above table that the plumbagin drug loading amount in the folic acid-modified plumbagin embedding complexes of Examples 1-3 of the present invention is relatively high.

[0039] Test Example 2 In vitro anti-tumor test The human breast cancer cell line MCF-7 and the human embryonic lung cell line WI-38 were seeded into 96 wells, 180 μL of cell suspension was added to each well, and cultured in a 37°C, 5% CO2 humidified air cell culture incubator for 24 hours. Continue to add 20 μL of different concentrations of folic acid-modified plumbagin embedding complexes prepared in Examples 1-3 and Comparative Examples 1-5. After 48 hours, 10 μL of MTT dye was added and incubated for 4 hours, the culture medium was removed, and 100 μL of dimethyl sulfoxide was added to each well and shaken for 15 minutes. Use an ELISA reader (dual wavelength 570nm / 630nm) to measure and calculate the IC 50 The results are shown in Table 2.

[0040] Table 2

[0041] It can be seen from the above table that the folic acid-modified plumbagin embedding complexes prepared in Examples 1-3 of the present invention have good in vitro anti-tumor effects. Example

[0042] An anti-tumor composition, characterized in that it comprises the folic acid-modified plumbagin embedding complex prepared in Example 1, paclitaxel and cisplatin, with a mass ratio of 1:7:8. Example

[0043] An anti-tumor composition, characterized in that it comprises the folic acid-modified plumbagin embedding complex prepared in Example 2, paclitaxel and cisplatin, with a mass ratio of 2:9:10. Example

[0044] An anti-tumor composition, characterized in that it comprises the folic acid-modified plumbagin embedding complex prepared in Example 3, paclitaxel and cisplatin, with a mass ratio of 1.5:8:9.

[0045] Comparative Examples 6-10 Compared with Example 6, the difference is that the folic acid-modified plumbagin embedding complex is prepared from Comparative Examples 1-5 respectively.

[0046] Test Example 3 Take logarithmically growing human lung squamous cell carcinoma H226 cells and adjust the cell concentration to 2×10 7 / mL, the cell suspension 150μL / mouse was subcutaneously injected into the upper right armpit of the mice, and the mice were grouped after successful modeling, as follows: normal control group, model group, positive drug cisplatin group [3mg / (kg / 2d)], Examples 4-6 and Comparative Examples 6-10 [2mg / (kg / 2d), the corresponding anti-tumor compositions], 10 mice in each group, intraperitoneal injection, the normal control group and the model group were given an equal amount of physiological saline, and the administration was 7d.

[0047] Calculation of tumor volume, tumor inhibition rate and spleen index: The size of the living tumor (the maximum long diameter a and the minimum short diameter b of the tumor) was measured before and on the day after administration. The mice were treated and weighed on the second day after administration. The tumor and spleen were collected. The tumor volume, tumor inhibition rate and spleen index were calculated using the formula: Tumor volume V = a × b 2 / 2 Volume tumor inhibition rate (%) = (m2-m1) / m2×100% m2——average tumor volume of the drug-treated group; m1——average tumor volume of the model group.

[0048] Spleen index = spleen mass, mg / mouse body mass, g The results are shown in Table 1.

[0049] Table 1

[0050] It can be seen from the above table that the anti-tumor compositions prepared in Examples 4-6 of the present invention have good anti-tumor effects and do not cause much damage to the spleen.

[0051] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for extracting plumbagin, characterized in that: The following steps are involved: S1. Alcohol extraction: Wash, dry and crush the plumbaginous plant to obtain plumbaginous plant powder, add it to an ethanol solution, heat and reflux it for extraction, repeat the extraction, filter, combine the filtrate and concentrate it to obtain an alcohol extract of plumbaginous plant; S2. Purification: The molecularly imprinted microspheres were loaded into a column, and the plumbagin alcohol extract was added, and the ethanol solution mixture was eluted, the eluate was collected, and the solvent was removed under reduced pressure to obtain plumbagin; S3. Preparation of albumin-PEG complex: dissolve albumin in water, add NHS and EDC·HCl, stir to activate, add NH2-PEG-COOH, stir to react, remove unreacted raw materials by ultrafiltration, and prepare albumin-PEG complex; S4. Encapsulation: adding albumin-PEG complex, EDC·HCl and DMAP to water, adding plumbagin, stirring to react, and removing unreacted raw materials by ultrafiltration to obtain an encapsulation complex; S5. Folic acid modification: Dissolve folic acid in dimethyl sulfoxide and triethanolamine, add NHS and DCC, stir the reaction in the dark, evaporate under pressure, add the product and the embedding complex into water, adjust the pH value, stir in the dark, incubate, and obtain the folic acid-modified plumbagin embedding complex.

2. The extraction method according to claim 1, characterized in that The concentration of the ethanol solution in step S1 is 60-70wt%, the heating reflux extraction time is 3-5h, the extraction is repeated 2-3 times, and the concentration is to 1 / 2 to 1 / 3 of the original volume.

3. The extraction method according to claim 1, characterized in that The concentration of the ethanol solution in step S2 is 65-75wt%, and the preparation method of the molecularly imprinted microspheres is as follows: T1. Plumbingol, functional monomers, crosslinking agents, and porogens were mixed and added to water. Under inert gas protection, an initiator was added, the polymerization reaction was heated, filtered, dried, and ball-milled to obtain polymer microspheres. T2. Add the polymer microspheres prepared in step T1 into a Soxhlet extractor, use an eluent to remove plumbagin, wash, and dry to obtain molecularly imprinted microspheres.

4. The extraction method according to claim 3, characterized in that The mass ratio of plumbagin, functional monomer, cross-linking agent, porogen and initiator is 6-7:29-32:0.2-0.7:1-2:0.05-0.15, the initiator is selected from at least one of sodium persulfate, potassium persulfate and ammonium persulfate, the functional monomer includes 4-vinylpyridine and butyl methacrylate in a mass ratio of 12-15:4-7, the cross-linking agent is ethylene glycol dimethacrylate, the porogen is acetone, the temperature of the heating polymerization reaction is 55-65°C, and the time is 1-3h.

5. The extraction method according to claim 1, characterized in that In step S3, the mass ratio of albumin, NHS, EDC·HCl and NH2-PEG-COOH is 10:3-5:5-7:12-15, the stirring activation temperature is 0-4°C, the time is 20-40min, and the stirring reaction time is 3-4h.

6. The extraction method according to claim 1, characterized in that In step S4, the mass ratio of the albumin-PEG complex, EDC·HCl, DMAP, and plumbagin is 12-15:2-4:0.5-1:5-7, and the stirring reaction time is 30-50 min.

7. The extraction method according to claim 1, characterized in that The mass ratio of folic acid, dimethyl sulfoxide, triethanolamine, NHS and DCC in step S5 is 0.5:1.8-2.2:0.05-0.1:0.05-0.07:0.06-0.1, the mass ratio of the product and the embedding complex is 3-5:10, the time for the light-proof stirring reaction is 1-3h, the pH value is adjusted to 9.5-10.5, the time for the light-proof stirring is 1-3h, the incubation temperature is 3-5°C, and the time is 10-12h.

8. A folic acid-modified plumbagin embedding complex obtained by the extraction method according to any one of claims 1 to 7.

9. An antitumor composition, characterized in that: It comprises the folic acid modified plumbagin embedding complex as described in claim 8 and paclitaxel and cisplatin.

10. The antitumor composition according to claim 9, characterized in that: The mass ratio of the folic acid-modified plumbagin embedding complex to paclitaxel and cisplatin is 1-2:7-9:8-10.